Trial Profile
Increasing pazopanib exposure by splitting intake moments
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2020
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma; Soft tissue sarcoma
- Focus Pharmacokinetics
- 04 Feb 2020 Primary endpoint, increase in pharmacokinetic exposure, measured as Cmin and AUC0-24h, when switching patients from a once daily (QD) dosing scheme to a twice daily (BID) dosing scheme, has been met as per results published in the Clinical Pharmacokinetics
- 04 Feb 2020 Results published in the Clinical Pharmacokinetics
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology